WO2004022100A1 - Formulation nanopharmaceutique et son procede de preparation - Google Patents
Formulation nanopharmaceutique et son procede de preparation Download PDFInfo
- Publication number
- WO2004022100A1 WO2004022100A1 PCT/CN2003/000663 CN0300663W WO2004022100A1 WO 2004022100 A1 WO2004022100 A1 WO 2004022100A1 CN 0300663 W CN0300663 W CN 0300663W WO 2004022100 A1 WO2004022100 A1 WO 2004022100A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- preparation
- complex
- formulation
- amphiphilic substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03793565A EP1543841A4 (en) | 2002-08-15 | 2003-08-13 | SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR |
US10/524,808 US20050255164A1 (en) | 2002-08-15 | 2003-08-13 | Solid nano pharmaceutical formulation and preparation method thereof |
JP2004533170A JP2006500387A (ja) | 2002-08-15 | 2003-08-13 | 固形ナノ医薬およびその調製方法 |
AU2003257791A AU2003257791A1 (en) | 2002-08-15 | 2003-08-13 | Soild nano pharmaceutical formulation and preparation method thereof |
CA002495899A CA2495899A1 (en) | 2002-08-15 | 2003-08-13 | Solid nano pharmaceutical formulation and preparation method thereof |
HK06103801.7A HK1083749A1 (en) | 2002-08-15 | 2006-03-27 | Solid nano pharmaceutical formulation and preparation method thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021288453A CN100479807C (zh) | 2002-08-15 | 2002-08-15 | 药物输送系统——固体纳米药物的制备方法 |
CN02128845.3 | 2002-08-15 | ||
CN02149146.1 | 2002-11-25 | ||
CNA021491461A CN1502332A (zh) | 2002-11-25 | 2002-11-25 | 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004022100A1 true WO2004022100A1 (fr) | 2004-03-18 |
Family
ID=31979238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000663 WO2004022100A1 (fr) | 2002-08-15 | 2003-08-13 | Formulation nanopharmaceutique et son procede de preparation |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050255164A1 (zh) |
EP (1) | EP1543841A4 (zh) |
JP (1) | JP2006500387A (zh) |
KR (1) | KR20060021278A (zh) |
CN (1) | CN100518831C (zh) |
AU (1) | AU2003257791A1 (zh) |
CA (1) | CA2495899A1 (zh) |
HK (1) | HK1083749A1 (zh) |
WO (1) | WO2004022100A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4884975B2 (ja) * | 2004-10-01 | 2012-02-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 微粒子含有組成物およびその製造方法 |
WO2012110469A1 (en) | 2011-02-17 | 2012-08-23 | F. Hoffmann-La Roche Ag | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
WO2013149981A1 (en) | 2012-04-03 | 2013-10-10 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability, safety and tolerability |
WO2014114575A1 (en) | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
CN104013601A (zh) * | 2014-06-06 | 2014-09-03 | 重庆医科大学 | 姜黄色素羟丙环糊精磷脂纳米粒及其制备方法 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2633380A1 (en) * | 2005-12-16 | 2007-07-05 | University Of Kansas | Nanoclusters for delivery of therapeutics |
KR100917809B1 (ko) | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
WO2007142440A1 (en) * | 2006-06-02 | 2007-12-13 | Sk Chemicals Co., Ltd. | Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same |
EP2057987B1 (en) * | 2006-08-30 | 2015-03-04 | Kyushu University, National University Corporation | Pharmaceutical composition containing statin-encapsulated nanoparticle |
GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
EP1952803A1 (en) | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
CN101702878B (zh) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
KR101502533B1 (ko) * | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
CN106092861B (zh) * | 2016-05-26 | 2019-02-26 | 国家纳米科学中心 | 用于纳米颗粒的光谱椭偏拟合方法 |
CN107952064B (zh) * | 2016-10-14 | 2023-10-20 | 江苏豪森药业集团有限公司 | 含有聚乙二醇洛塞那肽的药物制剂及其制备方法 |
WO2018204535A1 (en) | 2017-05-03 | 2018-11-08 | Cydex Pharmaceuticals, Inc. | Composition containing cyclodextrin and busulfan |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0132027A1 (en) * | 1983-05-20 | 1985-01-23 | Taisho Pharmaceutical Co. Ltd | Fat emulsion containing prostaglandin |
WO1992016196A1 (en) * | 1991-03-20 | 1992-10-01 | Novo Nordisk A/S | A composition comprising a peptide for nasal administration |
EP0602700A2 (en) * | 1992-12-17 | 1994-06-22 | NanoSystems L.L.C. | Novel formulations for nanoparticulate X-ray blood pool contrast agents using high molecular weight surfactants |
WO2000066635A1 (fr) * | 1999-04-29 | 2000-11-09 | Commissariat A L'energie Atomique | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes |
CN1424035A (zh) * | 2002-12-13 | 2003-06-18 | 北京东方天翔医药技术开发有限公司 | 尼莫地平冻干组合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950432A (en) * | 1987-10-16 | 1990-08-21 | Board Of Regents, The University Of Texas System | Polyene microlide pre-liposomal powders |
DE4140185C2 (de) * | 1991-12-05 | 1996-02-01 | Alfatec Pharma Gmbh | Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung |
PT695169E (pt) * | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
AU2531295A (en) * | 1994-05-27 | 1995-12-21 | Farmarc Nederland Bv | Pharmaceutical composition |
US5902604A (en) * | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
HUP9701945A3 (en) * | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
FR2775435B1 (fr) * | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
EP1105965B1 (en) * | 1998-06-16 | 2002-12-18 | Microwave Solutions Limited | Oscillator circuit |
US7025988B2 (en) * | 2000-02-04 | 2006-04-11 | Lipoxen Technologies Limited | Liposomes |
-
2003
- 2003-08-13 JP JP2004533170A patent/JP2006500387A/ja active Pending
- 2003-08-13 CA CA002495899A patent/CA2495899A1/en not_active Abandoned
- 2003-08-13 EP EP03793565A patent/EP1543841A4/en not_active Withdrawn
- 2003-08-13 WO PCT/CN2003/000663 patent/WO2004022100A1/zh active Application Filing
- 2003-08-13 CN CNB038188139A patent/CN100518831C/zh not_active Expired - Fee Related
- 2003-08-13 US US10/524,808 patent/US20050255164A1/en not_active Abandoned
- 2003-08-13 AU AU2003257791A patent/AU2003257791A1/en not_active Abandoned
- 2003-08-13 KR KR1020057002588A patent/KR20060021278A/ko not_active Application Discontinuation
-
2006
- 2006-03-27 HK HK06103801.7A patent/HK1083749A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0132027A1 (en) * | 1983-05-20 | 1985-01-23 | Taisho Pharmaceutical Co. Ltd | Fat emulsion containing prostaglandin |
WO1992016196A1 (en) * | 1991-03-20 | 1992-10-01 | Novo Nordisk A/S | A composition comprising a peptide for nasal administration |
EP0602700A2 (en) * | 1992-12-17 | 1994-06-22 | NanoSystems L.L.C. | Novel formulations for nanoparticulate X-ray blood pool contrast agents using high molecular weight surfactants |
WO2000066635A1 (fr) * | 1999-04-29 | 2000-11-09 | Commissariat A L'energie Atomique | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes |
CN1424035A (zh) * | 2002-12-13 | 2003-06-18 | 北京东方天翔医药技术开发有限公司 | 尼莫地平冻干组合物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1543841A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4884975B2 (ja) * | 2004-10-01 | 2012-02-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 微粒子含有組成物およびその製造方法 |
WO2012110469A1 (en) | 2011-02-17 | 2012-08-23 | F. Hoffmann-La Roche Ag | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
WO2013149981A1 (en) | 2012-04-03 | 2013-10-10 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability, safety and tolerability |
WO2014114575A1 (en) | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
CN104013601A (zh) * | 2014-06-06 | 2014-09-03 | 重庆医科大学 | 姜黄色素羟丙环糊精磷脂纳米粒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2003257791A1 (en) | 2004-03-29 |
CA2495899A1 (en) | 2004-03-18 |
CN1674941A (zh) | 2005-09-28 |
EP1543841A1 (en) | 2005-06-22 |
JP2006500387A (ja) | 2006-01-05 |
EP1543841A4 (en) | 2011-03-16 |
KR20060021278A (ko) | 2006-03-07 |
US20050255164A1 (en) | 2005-11-17 |
HK1083749A1 (en) | 2006-07-14 |
CN100518831C (zh) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mohammad et al. | Drug nanocrystals: Fabrication methods and promising therapeutic applications | |
AU2003304108B2 (en) | Nanoparticulate bioactive agents | |
US6146663A (en) | Stabilized nanoparticles which may be filtered under sterile conditions | |
WO2004022100A1 (fr) | Formulation nanopharmaceutique et son procede de preparation | |
Möschwitzer | Drug nanocrystals in the commercial pharmaceutical development process | |
Chen et al. | Nanonization strategies for poorly water-soluble drugs | |
G Nava-Arzaluz et al. | Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles | |
JP2006514698A5 (zh) | ||
Yadav et al. | Nanosuspension: A promising drug delivery system | |
Alshora et al. | Nanotechnology from particle size reduction to enhancing aqueous solubility | |
US20080038333A1 (en) | Formulations For Poorly Soluble Drugs | |
US20020119916A1 (en) | Elemental nanoparticles of substantially water insoluble materials | |
Liu et al. | A wet-milling method for the preparation of cilnidipine nanosuspension with enhanced dissolution and oral bioavailability | |
Ueda et al. | Optimization of the preparation of loperamide-loaded poly (L-lactide) nanoparticles by high pressure emulsification-solvent evaporation | |
JP2000501989A (ja) | 無菌条件下にろ過可能な安定化されたナノ粒子 | |
CN101322682A (zh) | 难溶性药物纳米粒的制备方法 | |
EP3616688A1 (en) | Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents | |
US20160287552A1 (en) | Drug delivery system comprising gelatine nano-particles for slowly releasing hardly-water soluble substances and its preparation method | |
WO2006034147A2 (en) | Compositions and methods for the preparation and administration of poorly water soluble drugs | |
CN1502332A (zh) | 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法 | |
Nedra Karunaratne et al. | Nanotechnological strategies to improve water solubility of commercially available drugs | |
Deshpande et al. | Nanocarrier technologies for enhancing the solubility and dissolution rate of API | |
Chaturvedi et al. | Insight into delivery approaches for biopharmaceutics classification system class II and IV drugs | |
Chauhan et al. | Manufacturing Process of Nanoparticles | |
Hapse et al. | Nanotechnology Based Approaches For Enhancements of Bioavailability of Sustain Release Formulation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20038188139 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2495899 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004533170 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003793565 Country of ref document: EP Ref document number: 10524808 Country of ref document: US Ref document number: 1020057002588 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003793565 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002588 Country of ref document: KR |